Skip to main content

Table 2 Analysis of features among BRCA1-, BRCA2- and non-BRCA1/2-associated cancers and in unselected cancers

From: Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families

  N (frequency, %) P
Feature BRCA1 BRCA2 Non-BRCA1/2 Unselected  
Histology      
   Ca ductale 37 (72.5) 37 (62.7) 102 (67.1) 561 (65.1)  
   Ca lobulare 8 (15.7) 17 (28.8) 30 (19.7) 219 (25.4)  
   Ca medullare 5 (9.8) - 3 (2.0) 20 (2.3) 0.013*, 0.001**
   Others 1 (2.0) 5 (8.5) 17 (11.2) 62 (7.2)  
Grade      
   I 3 (6.1) 12 (23.1) 46 (32.4) 152 (23.3)  
   II 11 (22.4) 26 (50.1) 66 (46.5) 289 (44.4)  
   III 35 (71.4) 14 (26.9) 30 (21.1) 210 (32.3)  
   I–II 14 (28.6) 38 (73.1) 112 (78.9) 441 (67.7) ≤ 0.0005*, <0.0005**, 0.009****
Immunohistochemistry      
   ER- 28 (66.7) 17 (32.1) 40 (27.0) 167 (19.4) ≤ 0.0005*, <0.0005**, 0.026***, 0.035****
   ER+ 14 (33.3) 36 (67.9) 108 (73.0) 692 (80.6)  
   PgR- 37 (84.1) 28 (51.9) 67 (45.3) 312 (36.2) ≤ 0.0005*, <0.0005**, 0.021***, 0.036****
   PgR+ 7 (15.9) 26 (48.1) 81 (54.7) 549 (63.8)  
   p53- 27 (62.8) 42 (82.4) 118 (78.7) 628 (74.0) 0.034*, <0.0005**
   p53+ 16 (37.2) 9 (17.6) 32 (21.3) 221 (26.0)  
   erbB2- 35 (81,4) 45 (84,9) 109 (82,6) NA  
   erbB2+ 8 (18,6) 8 (15,1) 23 (17,4) NA  
  1. *BRCA1 versus non-BRCA1/2 tumours; **BRCA1 versus unselected breast tumours; ***BRCA2 versus unselected breast tumours; ****non-BRCA1/2 tumours versus unselected breast tumours.
  2. Ca, carcinoma; ER, oestrogen receptor; NA, not available; PgR, progesterone receptor.